HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Online-Only Appendix All Versions of this Article: dc07-0608v1 30/10/2626    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tesfaye, S. Search for Related Content PubMed PubMed Citation Articles by Tesfaye, S. Social Bookmarking                What's this?

Factors that Impact Symptomatic Diabetic Peripheral Neuropathy in Placebo-treated Patients from Two 1-year Clinical Trials

¹Diabetes Research Unit, Royal Hallamshire Hospital, Sheffield, United Kingdom
²University of Vermont, College of Medicine, Burlington, Vermont
³Lilly Research Laboratories, Indianapolis, Indiana
⁴Indiana University, Indianapolis, Indiana

solomon.tesfaye{at}sth.nhs.uk

ABSTRACT

Objective:To evaluate the change in neuropathy symptoms and disease progression in placebo-treated patients from two 1-year studies that tested the impact of ruboxistaurin (RBX) in mild diabetic peripheral neuropathy (DPN).

Research Design and Methods:Data from 262 placebo-treated patients from two identical phase 3, randomized, double-blind trials were combined and analyzed.

Results:After 1 year, change in Neuropathy Impairment Score of Lower Limbs (NIS[LL];-0.63 points; p = 0.005), vibration detection threshold (VDT, -0.42 JND Units; p = 0.003) and Neuropathy Total Symptom Score-6 (NTSS-6, -3.73 points; p < 0.001) improved while some electrophysiology measures and Heart Rate Deep Breathing (HRDB - 0.78 beats; p = 0.003) worsened when compared with baseline values. There was a small but significant worsening of A1C (0.28%; p < 0.001) and a greater percentage of patients were using analgesics at the end of the trials (33.6%; p = 0.003). At 1 year, the change in NTSS-6 directly correlated with changes in NIS(LL) and VDT, and inversely correlated with the peroneal nerve conduction velocity. On logistic regression analyses, a 50% reduction in NTSS-6 score was less likely in patients that used anti-hypertensive or chronic symptom medication at baseline.

Conclusions:In placebo-treated patients with mild symptomatic DPN: 1) there was a progressive improvement in symptoms over 12 months whilst nerve conduction studies and HRDB declined; 2) clinically significant worsening of DPN would require greater than 1 year of observation.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. Kong, M. Andrassy, J. S. Chang, C. Huang, T. Asai, M. J. Szabolcs, S. Homma, R. Liu, Y. S. Zou, M. Leitges, et al. PKC{beta} modulates ischemia-reperfusion injury in the heart Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1862 - H1870. [Abstract] [Full Text] [PDF]

				A. J.M. Boulton Whither Clinical Research in Diabetic Sensorimotor Peripheral Neuropathy?: Problems of end point selection for clinical trials Diabetes Care, October 1, 2007; 30(10): 2752 - 2753. [Full Text] [PDF]